Clinical Trial

Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-21.
Trial Details
NCT Number NCT07147049
Lead Sponsor Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
Conditions Moderate to Severe Acute Postoperative Pain
Enrollment 72 participants
Start Date 2025-08-08
Primary Completion 2025-12 (estimated)
Study Completion 2026-01 (estimated)
Updated on ClinicalTrials.gov 2025-12-22